Trial Profile
A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery as Treatment for Relapsed and Refractory Non-Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CCODG-NSCLC
- 03 May 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 03 May 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 19 Oct 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.